Clinical trials currently active and in development for EGFR in glioblastoma include the study of several novel agents, including the TKI epitinib, bi-armed activated T cells against EGFR/CD3, EGFR(V)-EDV-Dox, the monoclonal antibody GC1118, doxorubicin-loaded anti-EGFR immunoliposomes, and the anti-EGFRvIII/CD3 bispecific T-cell engager (BiTE) AMG 596, among others [121]. This evidence concerns the gene EGFR and glioblastoma.